期刊
BLOOD PRESSURE
卷 26, 期 5, 页码 284-293出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/08037051.2017.1329623
关键词
High-dose calcium antagonist; nifedipine controlled-release; amlodipine; ambulatory blood pressure; morning blood pressure surge; urinary albumin creatinine ratio; renal protection
资金
- Bayer Yakuhin Ltd.
Background: Data are sparse regarding ambulatory blood pressure (BP) reduction of up-titration from a standard dose to a high dose in both nifedipine controlled-release (CR) and amlodipine. This was a prospective, randomized, multicenter, open-label trial.Patients and methods: Fifty-one uncontrolled hypertensives medicated by two or more antihypertensive drugs including a renin-angiotensin system inhibitor and a calcium antagonist were randomly assigned to either the nifedipine CR (80mg)/candesartan (8mg) group or the amlodipine (10mg)/candesartan (8mg) group.Results: The changes in 24-hr BP were comparable between the groups. The nifedipine group demonstrated a significant decrease in their urinary albumin creatinine ratio, whereas the amlodipine group demonstrated a significant decrease in their NTproBNP level. However, there was no significant difference in any biomarkers between the two groups.Conclusion: Nifedipine showed an almost equal effect on ambulatory blood pressure as amlodipine. Their potentially differential effects on renal protection and NTproBNP should be tested in larger samples.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据